Efficacy of once-daily glucagon-like peptide-1 receptor agonist lixisenatide as an add-on treatment to basal insulin in Asian and white adults with type 2 diabetes mellitus: An individual-level pooled analysis of phase III studies.
Fuqiang LiuYuan LiuMinzhi LiuGuangyu WuMinlu ZhangXia ZhangNan CuiHuiqiu YinLi ChenPublished in: Journal of diabetes investigation (2021)
Adding lixisenatide to BI significantly reduced HbA1c and 2-h PPG levels in both Asian and white participants with type 2 diabetes mellitus. No differences in treatment effect were observed between the two populations.